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The study of common human diseases has made 
considerable progress since 2007 when the first ‘The 
Genomics of Common Diseases’ conference was held. 
There are now over 1,300 genome-wide associations 
reported between SNPs and human diseases or related 
traits (http://www.genome.gov/GWAStudies). Despite 
some initial skepticism, these results are now beginning 
to open doors on new disease pathways and mechanisms, 
but it remains to be seen whether the next phase of the 
Human Genome Project, utilizing massively parallel 
next-generation sequencing to discover rare genomic 
variants, will have even more explanatory power, as some 
have predicted. The 2011 conference was held at the 
Wellcome Trust Genome Campus in Hinxton and many 
talks focused on whether this new technology will help to 
turn the corner in complex diseases, by elucidating their 
heritability, most of which is currently unexplained, and 
providing further mechanistic insights.
Limitations of genome-wide association studies
To the extent that genome-wide association studies 
(GWASs) are not providing all of the answers, keynote 
speaker Mark Daly (Broad Institute, USA) pointed to the 
genetic architecture as the main culprit. Most complex 
traits are likely to be underpinned by both common and 
rare variants, but the role of the latter has been relatively 
untouched by GWASs. As the architectural fog begins to 
lift, there appears to be two extreme scenarios: some 
diseases involve a small number of genetic pathways, 
while others appear to show an almost limitless 
complexity. An example is in GWASs of inflammatory 
bowel disease (IBD) that, in the course of 12 years, have 
revealed >100 susceptibility loci, an extraordinary 
achieve ment, although still only explaining about 25% of 
the heritability. Despite the apparent complexity, the 
identified genes predominantly fall into two main func-
tional categories: innate immunity and autophagy. How-
ever, the preliminary results of whole genome sequencing 
in IBD patients and controls is throwing up rare variants 
in new genes, as well as in known genes such as CARD9, 
where a whole spectrum of allele frequencies and effect 
sizes is apparent. In contrast, the diversity of rare copy 
number and other structural variants in neuropsychiatric 
disorders, such as schizophrenia or autism, suggests a 
very large number of pathways and mechanisms. Previous 
GWASs in these disorders have been disappointing. In 
schizophrenia, for example, there were few genome-wide 
significant hits and the results pointed to thousands of 
common alleles of very small effect (odds ratio: approxi-
mately 1.1 or less), consistent with a polygenic model, but 
identifying no clear pathways or mechanisms. However, 
the sample sizes may simply have been too small to 
overcome the genetic heterogeneity and small allele effect 
sizes involved. Recent studies using substantially more 
cases and controls (>50,000 individuals) look more 
promising, with the suggestion of a neural development 
pathway involving the MIR137 microRNA and some of 
its targets.
Searching for rare variants associated with 
common diseases
Several speakers reported new susceptibility loci, harbor-
ing an excess of rare variants, found by whole genome or 
exome sequencing in patients and controls at the 
phenotypic extremes. Sekar Kathiresan (Massachusetts 
General Hospital, USA) described exome sequencing of 
1,100 patients with early-onset myocardial infarction and 
1,100 ‘hypernormal’ controls. They used ‘allelic burden’ 
tests to detect clustering of individually rare functional 
variants within candidate genes and also ‘imputation’ 
(geno type prediction) into GWAS datasets to replicate 
the results. An excess of apparently functional rare 
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variants (<1% to 5% frequency) was found both in novel 
susceptibility genes (for example, CHRM5, DKK2 and 
LRIG2) and in known genes (for example, PCSK9). 
Replication of rare variant associations is demanding, 
however, requiring tens of thousands of individuals. 
Goncalo Abecasis (University of Michigan, USA) des-
cribed exome sequencing those at the extremes of the 
low-density lipoprotein cholesterol (LDL-C) distribution 
in an isolated Sardinian population (approximately 6,000 
individuals). So far, rare variants have been found mostly 
in known genes, such as LDLR, SORT1 and APOB. 
Cristen Willer (University of Michigan, USA) and 
colleagues are also exome sequencing those at the LDL-C 
extremes (top and bottom 1%) but in this case from four 
general population-based cohorts. They also found an 
excess of rare variants at one or other extreme, mostly in 
known genes, suggesting either that a point of 
diminishing returns has been reached or that extreme 
samples from much larger populations are needed to 
identify new pathways.
Michael Boehnke (University of Michigan, USA) des-
cribed a similar ‘extremes’ genome sequencing strategy in 
diabetes, using leaner, younger and family-history-
positive type 2 diabetics compared with heavier, older, 
ancestry-matched controls. He also discussed a family-
based sequencing project, which highlighted the advan-
tages of families not only for establishing haplotypes and 
confirming heterozygous sequence variants but also for 
establishing phenotype-genotype correlations. As many 
carriers of a rare variant (frequency 10-4) could be identi-
fied in a single family as in a screen of 15,000 unrelated 
individuals. Currently, only about 10% of the heritability 
of type 2 diabetes has been explained by the >50 GWAS 
associated genes but it remains to be seen whether rare 
variants explain more of the heritability.
The role of rare variants in trait architecture was also 
raised by Richard Durbin (Wellcome Trust Sanger Insti-
tute, UK), who summarized progress with the 1,000 
Genomes and UK10K Projects. Cladograms of the major 
human population expansions over the past 10,000 years 
show exponential growth and remote common ancestry, 
whereas isolate populations show recent common ances-
try, facilitating the search for shared haplotypes, long-
range phasing and imputation of rare variants identified 
by whole genome sequencing. Exponential growth also 
leads to an excess of rare or private mutations, which may 
therefore figure prominently in the genetic architecture 
of many traits.
The problem of locus heterogeneity
Several speakers emphasized another aspect of genetic 
architecture: locus heterogeneity (many genes influencing 
the trait). David Goldstein (Duke University, USA) des-
cribed studies of the sustained virological response (SVR) 
following hepatitis C virus infection, in which GWASs 
identified the IL28B gene, explaining half of the difference 
in SVR between Europeans and Africans. A similar study 
of HIV-1 resistance showed no genome-wide significant 
associations but a follow-up whole genome sequencing 
study is pointing to several promising candidates. How-
ever, the sample size being sequenced may be critical to 
reliably detect an allelic burden, because of the extreme 
locus heterogeneity.
Next-generation sequencing is also facilitating a quiet 
revolution in Mendelian genetics. Debbie Nickerson 
(Uni versity of Washington, USA) described the advan-
tages of exome over whole-genome sequencing, namely 
larger allelic effect sizes, easier interpretation and func-
tional follow-up, lower cost and computational savings. 
Sequencing a small number of well-chosen individuals 
can produce disproportionate information on physiolo-
gical as well as disease mechanisms. The role of the 
DLX5/DLX6 pathway and its important role in jaw 
development in humans (auriculocondylar syndrome), 
mice and zebrafish was discovered in this way. Exome 
sequencing a small number of parent-child trios has also 
facilitated the discovery of highly penetrant de novo 
mutations. Nickerson’s central message was again the 
need for strategies to circumvent the locus heterogeneity, 
including the use of isolates, families with extreme 
phenotypes, trait or disease subgroups, or intermediate 
quantitative traits.
Determining the functional role of new variants
One of the problems raised by next-generation sequen-
cing is evaluating the functional significance of newly 
identified rare variants. Nicholas Katsanis (Duke Univer-
sity, USA) presented an elegant approach to resolve the 
functionality of candidate genes and variants using 
morpholino-induced translation suppression in zebrafish. 
He described its use in systematically resolving which of 
the 29 candidate genes at a locus influencing head size 
was causal (KCTD13). The approach has limitations, 
however, and seems to be most suitable for anatomical 
traits.
The role of genomic sites regulating gene expression 
was discussed by Len Pennacchio (Lawrence Berkeley 
National Laboratory, USA) and John Stomatoyanno-
poulos (University of Washington, USA). Pennacchio 
described the use of chromatin immunoprecipitation 
(ChIP) sequencing P300 transcriptional coactivator targets 
to specifically detect enhancer sequences. These repre-
sent a substantial (20% to 50%) subset of all enhancers 
but show relatively poor sequence conservation despite 
being active across species as diverse as human and 
mouse. They are also hard to mutate, suggesting the 
impor tance of secondary structure. Stomatoyannopoulos 
presented the results of systematically surveying 
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regulatory sites marked by DNAse I hypersensitivity 
(DHS) in a broad range of cells and tissues (http://www.
roadmapepigenomics.org/). There are over 2.4 million 
human DHS sites, which commonly influence chromatin 
states and are exposed whenever a gene is being 
expressed in a particular cell type. A majority of GWAS-
identified SNPs are either in DHS sites or strongly 
associated with them. Many of these sites cluster within 
physiologically relevant transcription factor binding sites. 
Stomatoyannopoulos emphasized that the GWAS ‘story’ 
in common diseases is more concerned with identifying 
such pathways than with individual, small effect suscep-
tibility genes. An old question is perhaps finally being 
answered: the polygenic basis of complex traits may 
principally result from such expression differences.
Are we reaching the ‘tipping point’ for genomics of 
common diseases?
The field is fast moving but, like an old daguerreotype 
photograph that only captures solid unmoving objects, a 
few conclusions can be drawn. Complex traits consist of 
an unpredictable mix of common, uncommon and rare 
genetic variants with effect sizes that are inversely related 
to their frequency. Only members of the first group 
(common variants) have been well captured by GWASs 
and about three-quarters of these occur in non-coding 
regulatory regions. The associated genetic pathways have 
accordingly been hard to discern, leading to patchy 
progress in unraveling pathogenetic mechanisms. Next-
generation sequencing of whole genomes or exomes is 
now beginning to capture the uncommon and rare, if not 
the very rare, variants influencing common diseases. 
New arrays with a higher proportion of low frequency 
variants will help to replicate the results of genome 
sequencing studies. These resources should also allow 
more researchers to reach the ‘tipping point’ or critical 
sample size required to overcome the extent of locus and 
allelic heterogeneity and small individual genetic effect 
sizes that are an emerging feature of most complex traits. 
Time and technology will tell but one thing we can be 
sure of is a tsunami of genomic sequence data over the 
next few years.
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